MedicalPersonalized Medicine

Merck and EOS sister company AMCM partner to 3D print tablets

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Pharmaceutical company Merck and German custom additive manufacturing specialist AMCM (sister company of EOS) have announced a collaboration through which they will develop 3D printed tablet formulations. The partnership aims to create a tablet 3D printing process that conforms to Good Manufacturing Practice (GMP) standards for clinical trials and, eventually, for commercial manufacturing services.

3D printed pills are gaining traction in healthcare, as medical and drug companies realize the potential of additive manufacturing to personalize medicine and dosages. In this case, Merck is hoping to leverage 3D printing to achieve greater scalability for API (active pharmaceutical development) formulations by minimizing reliance on costly reformulations across the whole pharmaceutical development and production process. The pharma giant sees an opportunity to use 3D printing to create tablets in a more cost and time efficient manner.

Merck AMCM 3D printed tablets
Isabel de Paoli, Chief Strategy Officer at Merck

“Our partnership with AMCM/EOS has the potential to revolutionize the way tablets are produced. It will be a massive move towards digitalization of the industry,” commented Isabel de Paoli, Chief Strategy Officer at Merck. “Our goal is to develop the industrial application of this technology, which we will make available for clinical trials first, and then move to full digital solutions at commercial scale.”

Through the partnership, AMCM will supply a customized powder bed fusion process that will reportedly simplify the clinical development of drugs. The 3D printing technology is expected to pave the way to more flexible and sustainable tablet production, by enabling localized manufacturing that can address specific market requirements and by being adaptable to patient needs.

Marie Langer, CEO of EOS, said of the collaboration: “We are excited to support Merck on its innovation journey. This cooperation combines Merck’s formulation competences in Healthcare as well as its excipient expertise in Life Science with our long-standing additive manufacturing know-how. Together, we will help make drug development more flexible and faster.”

The 3D printed tablet project will be spearheaded by the Innovation Center at Merck’s headquarters in Darmstadt, Germany.

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!